AIM:To evaluate the efficacy, safety and economy of conbercept and ranibizumab in the treatment of macular edema(ME)secondary to retinal vein occlusion(RVO).

METHODS:The comparative studies on macular edema secondary to RVO were collected in Wanfang database, CNKI, Pubmed, The Cochrane Library, Google scholar and other databases. The best corrected visual acuity, macular fovea retinal thickness, the number of adverse reactions and the number of injections were systematically evaluated. Compare the effects of the two. RevMan 5.3 statistical software was used to analyze the data.

RESULTS:A total of 1 337 patients were included in 16 studies. The results of systematic evaluation showed that in 1+PRN injection regimen and in the treatment of BRVO secondary ME patients, the regression effect of ME was more obvious, and the injection times were less in 3+PRN injection regimen and treatment of CRVO secondary ME patients. In comparison with the effect of ranibizumab, there was no significant difference in the improvement of visual acuity and the occurrence of side effects when 3+PRN injection was used to treat ME secondary to CRVO. When 1+PRN injection was used to treat Brvo secondary ME, the total number of injections was not statistically significant.

CONCLUSION:Compared with ranibizumab, conbercept showed better effect in different injection regimens and different types of vein occlusion that is less injection times or better ME regression effect.